Literature DB >> 12797715

Multinational study of reliability and validity of the King's Health Questionnaire in patients with overactive bladder.

Pat Ray Reese1, Andreas M Pleil, Gary J Okano, Con J Kelleher.   

Abstract

OBJECTIVE: Overactive bladder (OAB) has substantial impact on health-related quality of life (HRQoL). The purpose of this research was to evaluate the psychometric properties of the King's Health Questionnaire (KHQ).
METHODS: The KHQ (n = 1284) was administered at baseline and 12 weeks post-treatment in a multinational, double-blind, randomized clinical trial of tolterodine for treatment of OAB. Country-specific psychometric analyses of HRQoL instruments were performed. Countries demonstrating marginal psychometric properties on the KHQ were pooled with same-language countries, re-evaluated, and aggregate analysis performed on the pooled data.
RESULTS: Internal consistency of the KHQ was high, item characteristics were good, most assumptions of summed scales were met, and it is externally valid and consistent. Few problems with the KHQ were noted although the performance of the personal relationships domain was complicated by the 'not applicable' response category.
CONCLUSIONS: Psychometric testing supports the reliability and validity of the KHQ as an OAB-specific measure of HRQoL.

Entities:  

Mesh:

Year:  2003        PMID: 12797715     DOI: 10.1023/a:1023422208910

Source DB:  PubMed          Journal:  Qual Life Res        ISSN: 0962-9343            Impact factor:   4.147


  18 in total

Review 1.  Review. Quality-of-life aspects of the overactive bladder and the effect of treatment with tolterodine.

Authors:  G Kobelt; I Kirchberger; J Malone-Lee
Journal:  BJU Int       Date:  1999-04       Impact factor: 5.588

2.  A population study of urinary incontinence and nocturia among women aged 20-59 years. Prevalence, well-being and wish for treatment.

Authors:  E Samuelsson; A Victor; G Tibblin
Journal:  Acta Obstet Gynecol Scand       Date:  1997-01       Impact factor: 3.636

3.  Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder.

Authors:  P Van Kerrebroeck; K Kreder; U Jonas; N Zinner; A Wein
Journal:  Urology       Date:  2001-03       Impact factor: 2.649

4.  Distress and delay associated with urinary incontinence, frequency, and urgency in women.

Authors:  P A Norton; L D MacDonald; P M Sedgwick; S L Stanton
Journal:  BMJ       Date:  1988-11-05

Review 5.  Psychometric considerations in evaluating health-related quality of life measures.

Authors:  R D Hays; R Anderson; D Revicki
Journal:  Qual Life Res       Date:  1993-12       Impact factor: 4.147

Review 6.  The overactive bladder: an overview for primary care health providers.

Authors:  A J Wein; E S Rovner
Journal:  Int J Fertil Womens Med       Date:  1999 Mar-Apr

Review 7.  Quality of life and urinary incontinence.

Authors:  C Kelleher
Journal:  Baillieres Best Pract Res Clin Obstet Gynaecol       Date:  2000-04

Review 8.  Comorbidities associated with overactive bladder.

Authors:  J S Brown; W F McGhan; S Chokroverty
Journal:  Am J Manag Care       Date:  2000-07       Impact factor: 2.229

Review 9.  Overactive bladder: special considerations in the geriatric population.

Authors:  J G Ouslander; Y T Shih; J Malone-Lee; K Luber
Journal:  Am J Manag Care       Date:  2000-07       Impact factor: 2.229

10.  Quality of life following bladder training in older women with urinary incontinence.

Authors:  J F Wyman; J A Fantl; D K McClish; S W Harkins; J S Uebersax; M G Ory
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  1997
View more
  37 in total

Review 1.  Fesoterodine for overactive bladder: A review of the literature.

Authors:  Kanchan Gupta; Kirandeep Kaur; Baldev Singh Aulakh; Sandeep Kaushal
Journal:  Curr Ther Res Clin Exp       Date:  2010-10

Review 2.  Patient-reported outcomes and different approaches to urinary parameters in overactive bladder: what should we measure?

Authors:  Vik Khullar
Journal:  Int Urogynecol J       Date:  2011-10-20       Impact factor: 2.894

Review 3.  Measuring urgency in clinical practice.

Authors:  Roger R Dmochowski; Mary P FitzGerald; Jean-Jacques Wyndaele
Journal:  World J Urol       Date:  2009-08-27       Impact factor: 4.226

4.  Bladder-related quality of life in people with neurological disorders: reliability and validity of the Turkish version of the King's Health Questionnaire in people with spinal cord injury.

Authors:  Hale Karapolat; Yeşim Akkoç; Sibel Eyigör; Göksel Tanıgör
Journal:  Turk J Urol       Date:  2018-03-09

Review 5.  Disease burden of overactive bladder: quality-of-life data assessed using ICI-recommended instruments.

Authors:  Ramandeep Basra; Con Kelleher
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

6.  Establishing the content validity of the King's Health Questionnaire in men and women with overactive bladder in the US.

Authors:  Mary Kay Margolis; Vasudha Vats; Karin S Coyne; Con Kelleher
Journal:  Patient       Date:  2011       Impact factor: 3.883

7.  Electrical stimulation compared with tolterodine for treatment of urge/urge incontinence amongst women--a randomized controlled trial.

Authors:  Karin Franzén; Jan-Erik Johansson; Inger Lauridsen; Jill Canelid; Bengt Heiwall; Kerstin Nilsson
Journal:  Int Urogynecol J       Date:  2010-06-29       Impact factor: 2.894

8.  Health-related quality of life of Japanese patients with overactive bladder treated with extended-release tolterodine or immediate-release oxybutynin: a randomized, placebo-controlled trial.

Authors:  Y Homma; K Kawabe
Journal:  World J Urol       Date:  2004-09-29       Impact factor: 4.226

Review 9.  Subjective measures of efficacy and quality of life in overactive bladder syndrome.

Authors:  Aimee Nguyen; Peter K Sand
Journal:  Curr Urol Rep       Date:  2008-09       Impact factor: 3.092

10.  Exploring the impact of changes in neurogenic urinary incontinence frequency and condition-specific quality of life on preference-based outcomes.

Authors:  William Hollingworth; Jonathan D Campbell; Jonathan Kowalski; Arliene Ravelo; Isabelle Girod; Andrew Briggs; Sean D Sullivan
Journal:  Qual Life Res       Date:  2010-01-22       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.